Genmab reports positive results of antitumor drug in preclinical studies
Preclinical studies characterized the exact HuMax-IL8 binding site on IL8, which overlaps with the docking site for the IL8 receptor, CXCR1. HuMax-IL8 was found to effectively block formation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.